

GLAXOSMITHKLINE PLC

Form 6-K

April 29, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 29 April 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') who acquired Ordinary Shares ('Shares') in GlaxoSmithKline plc ('GSK') at a price of 1496.49 pence per Share, following the re-investment of the dividend paid to shareholders on 14 April 2016.

Director/PDMR	Shares
Sir Andrew Witty	2,257.407
Mr R Connor	552.391
Mr S A Hussain	1,460.067
Mr D S Redfern	2,129.312
Dr M M Slaoui	4.719
Ms C Thomas	2,692.384
Mr P C Thomson	1,002.153
Dr P J T Vallance	3,827.535
Ms E Walmsley	2,705.444

Connected Person	Shares
Mrs K Thomson (Connected Person to Mr P C Thomson)	251.103

GSK was informed of these allocations on 28 April 2016.

V A Whyte  
Company Secretary

29 April 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 29, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc